INS and type 1 diabetes mellitus: investigated the use of ATG (2.5 mg/kg) + GCSF in 89 subjects withrecent-onset stage 3 T1D (29)randomized to ATG + GCSF, 29 received ATG alone and 31 received placebo), in combinationwith insulin.